Byung Soo Kim

Busan Veterans Hospital, Busan, Busan, South Korea

Are you Byung Soo Kim?

Claim your profile

Publications (274)490.58 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The human immunodeficiency virus type-1 (HIV-1) nucleocapsid protein (NC) is an essential and multifunctional protein involved in multiple stages of the viral life cycle such as reverse transcription, integration of proviral DNA, and especially genome RNA packaging. For this reason, it has been considered as an attractive target for the development of new anti-HIV drugs. Although a number of inhibitors of NC have been reported thus far, the search for NC-specific and functional inhibitor(s) with a good antiviral activity continues. Results: In this study, we report the identification of A1752, a small molecule with inhibitory action against HIV-1 NC, which shows a strong antiviral efficacy and an IC50 around 1 μM. A1752 binds directly to HIV-1 NC, thereby inhibiting specific chaperone functions of NC including Psi RNA dimerization and complementary trans-activation response element (cTAR) DNA destabilization, and it also disrupts the proper Gag processing. Further analysis of the mechanisms of action of A1752 also showed that it generates noninfectious viral particles with defects in uncoating and reverse transcription in the infected cells. Conclusions: These results demonstrate that A1752 is a specific and functional inhibitor of NC with a novel mode of action and good antiviral efficacy. Thus, this agent provides a new type of anti-HIV NC inhibitor candidate for further drug development.
    Retrovirology 11/2015; 12(1):90. DOI:10.1186/s12977-015-0218-9 · 4.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM). Objectives: This study aimed to elucidate the effect of chemotherapy with or without bortezomib in MM patients on their herpes zoster incidence and varicella zoster virus (VZV)-specific cell-mediated immunity (CMI). Study design: Peripheral blood mononuclear cells were collected at baseline and after 1 month of bortezomib-based or thalidomide-based chemotherapy and then analyzed using VZV-specific interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay. The clinical data from these patients were analyzed in relation to the ELISPOT results. Results: Of 58 patients analyzed, 39 patients received bortezomib and the other 19 patients, thalidomide. Among them, 5 patients developed herpes zoster during chemotherapy; all 5 were being treated with the bortezomib-based regimen and were not receiving prophylactic anti-viral agents. The median onset of herpes zoster was 32 days (range, 15-95 days) from the initiation of chemotherapy. Among patients who received bortezomib therapy, acyclovir prophylaxis significantly reduced the risk for herpes zoster (100-day cumulative incidence, 0% vs. 49.5%; p<0.001). Spot-forming cell (SFC) counts in the IFN-γ ELISPOT assay decreased from baseline after bortezomib (p=0.011) or thalidomide (p=0.096) treatment. Patients with baseline SFCs greater than 20/10(6) mononuclear cells exhibited significantly higher incidence of herpes zoster (100-day cumulative incidence, 34.8% vs. 0%; p=0.040). Conclusions: Bortezomib treatment significantly reduced VZV-specific CMI, and high baseline SFC counts in patients receiving this treatment without acyclovir prophylaxis were associated with a significantly increased risk for herpes zoster.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 10/2015; 73. DOI:10.1016/j.jcv.2015.10.018 · 3.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Decursin, a bioactive phytochemical isolated from Angelica gigas Nakai (danggwi), has shown preclinical anticancer efficacy in various cancer models. However, the antitumor effect of decursin in melanoma models remains undefined. The antitumor activities of decursin were investigated in B16F10 cells in vitro and in vivo. In this study, we show that treatment with decursin inhibited cell proliferation in a dose-dependent manner in B16F10 cells, but not in normal cells. Decursin also induced apoptosis in B16F10 cells, as determined by annexin V-staining assay and transferase-mediated nick-end labeling (TUNEL) staining assay. Decursin increased the phosphorylation of p38 as well as the expression of Bax while decreasing the phosphorylation of extracellular signaling-regulated kinase (ERK) and the expression of Bcl-2 in B16F10 cells. Moreover, decursin activated caspase-3 in B16F10 cells and xenograft tumor tissue. Together, these findings support further investigations into the potential use of decursin in the treatment of melanoma cells.
    Journal of medicinal food 09/2015; 18(10). DOI:10.1089/jmf.2014.3397 · 1.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/objectives: The effect of aspirin and clopidogrel in a fixed-dose combination (FDC) on platelet function was compared with separate formulations in patients that had undergone percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Methods: This was a phase IV, prospective, multicenter, single-arm, non-inferiority study. Patients that had taken aspirin 100mg and clopidogrel 75mg once daily as separate formulations for >6months after PCI with DES were enrolled, and then switched to an aspirin/clopidogrel FDC once-daily for 4weeks. Platelet reactivity was determined using the VerifyNow® P2Y12 assay at baseline (immediately prior to switching) and 4weeks later. Results: A total of 648 patients (the full-analysis population; age, 63.6±9.0years; male, 76.5%) finished the study, and 565 (the per-protocol population) completed without protocol violations. In the per-protocol population, the % inhibitions of P2Y12 and ARU were not significantly different between baseline and after 4weeks of FDC treatment (29.2±20.0% to 29.0±19.9%, P=0.708; 445.1±69.2 to 446.2±63.0, P=0.799, respectively) and the difference in P2Y12 inhibition observed did not exceed the predetermined limit of non-inferiority (95% CI, -0.9 to 1.3). In the full-analysis population, the % inhibitions of P2Y12, PRU, and ARU were not significantly changed after 4weeks of FDC treatment. Conclusions: This study demonstrates that the efficacy of platelet inhibition by an aspirin/clopidogrel FDC was not inferior to that of separate aspirin and clopidogrel formulations in patients that had undergone PCI with DES.
    International journal of cardiology 09/2015; 202. DOI:10.1016/j.ijcard.2015.09.024 · 4.04 Impact Factor
  • Source
    Seon Hee Kim · Byung Soo Kim · Ji Chang You ·
    [Show description] [Hide description]
    DESCRIPTION: Small molecular inhibitor targeting nucleocapsid of HIV-1
  • Ji-Hye Jung · Byung Soo Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The propagation of human pluripotent stem cells (hPSCs) in conditioned medium derived from human cells in feeder-free culture conditions has been of interest. Nevertheless, an ideal humanized ex vivo feeder-free propagation method for hPSCs has not been developed; currently, additional exogenous substrates including basic fibroblast growth factor (bFGF), a master hPSC-sustaining factor, is added to all of culture media and synthetic substrata such as Matrigel or laminin are used in all feeder-free cultures. Recently, our group developed a simple and efficient protocol for the propagation of hPSCs using only conditioned media derived from the human placenta on a gelatin-coated dish without additional exogenous supplementation or synthetic substrata specific to hPSCs. This protocol has not been reported previously and might enable researchers to propagate hPSCs efficiently in humanized culture conditions. Additionally, this model obviates hPSC contamination risks by animal products such as viruses or unknown proteins. Furthermore, this system facilitates easy mass production of hPSCs using the gelatin coating, which is simple to handle, dramatically decreases the overall costs of ex vivo hPSC maintenance.
    Journal of Visualized Experiments 08/2015; 2015(102). DOI:10.3791/53204 · 1.33 Impact Factor
  • Cheol Min Joo · Byung Soo Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This article considers the unrelated parallel machine scheduling problem with sequence- and machine-dependent setup times and machine-dependent processing times. Furthermore, the machine has a production availability constraint to each job. The objective of this problem is to determine the allocation policy of jobs and the scheduling policy of machines to minimize the total completion time. To solve the problem, a mathematical model for the optimal solution is derived, and hybrid genetic algorithms with three dispatching rules are proposed for large-sized problems. To assess the performance of the algorithms, computational experiments are conducted and evaluated using several randomly generated examples.
    Computers & Industrial Engineering 07/2015; 85. DOI:10.1016/j.cie.2015.02.029 · 1.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥65 years), poor performance score (≥2), high International prognosis index (≥3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment. © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email:
    Japanese Journal of Clinical Oncology 07/2015; 45(10). DOI:10.1093/jjco/hyv102 · 2.02 Impact Factor
  • Byung Soo Kim · Syungkyu Chae · Woon-Seek Lee ·

    06/2015; 41(3):233-242. DOI:10.7232/JKIIE.2015.41.3.233
  • Byung Soo Kim · Cheol Min Joo ·
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the most important operational management problems of a cross docking system is the truck scheduling problem. Cross docking is a logistics management concept in which products delivered to a distribution center by inbound trucks are immediately sorted out, routed and loaded into outbound trucks for delivery to customers. The truck scheduling problem in a multi-door cross docking system considered in this paper comprises the assignment of trucks to dock doors and the determination of docking sequences for all inbound and outbound trucks in order to minimize the total operation time. A mathematical model for optimal solution is derived, and the genetic algorithms (GAs) and the adaptive genetic algorithms (AGAs) as solution approaches with different types of chromosomes are proposed. The performance of the meta-heuristic algorithms are evaluated using randomly generated several examples.
    Asia Pacific Journal of Operational Research 06/2015; 32(03):1550016. DOI:10.1142/S0217595915500165 · 0.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared the efficacy of high-dose cytarabine alone to that of intermediate-dose cytarabine combined with anthracyclines as consolidation therapy. Patients enrolled in the Korea University acute myeloid leukemia (AML) registry received remission induction chemotherapy with the same standard induction regimen (idarubicin and cytarabine 3 + 7). Postremission therapy was performed for three or four cycles according to one of the following regimens: high-dose cytarabine (3 g/m(2)) or combination of intermediate-dose cytarabine (1 g/m(2)) with anthracyclines (idarubicin or mitoxantrone). Among the 443 AML patients enrolled in the registry, 145 patients received consolidation chemotherapy. The median overall survival (OS) and relapse-free survival (RFS) in the high-dose cytarabine group were significantly longer than those in the anthracycline combination group (OS, not reached vs. 16.6 months, p = 0.045; RFS, 38.6 months vs. 11.0 months, p = 0.011). The median duration of neutropenia was longer in the anthracycline combination group than in the high-dose cytarabine group (8 vs. 10 days, p = 0.001). This study suggests that high-dose cytarabine consolidation may produce superior outcomes than combination treatment with intermediate-dose cytarabine and anthracyclines and that the addition of anthracyclines during AML consolidation has limited value as compared to cytarabine intensification.
    Annals of Hematology 05/2015; 94(9). DOI:10.1007/s00277-015-2389-9 · 2.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
    Korean Circulation Journal 05/2015; 45(3):225-33. DOI:10.4070/kcj.2015.45.3.225 · 0.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose. This study aimed to find convenient clinical indexes, rather than plasma trough levels of IM, to define the appropriate IM dosage. Seventy CML CP patients who experienced an IM dose reduction, or a temporary cessation, were enrolled from 2002 to 2010. The IM treatment was resumed and maintained at either ≥400 mg in 25 patients (35.7%; group ≥400 mg) or at ≤300 mg in 45 patients (64.3%; group ≤300 mg). The various clinical characteristics of these patients were evaluated. The plasma trough level of IM was monitored in 20 patients from group ≤300 mg. Via multivariate analysis, the IM dosage divided by the body surface area (BSA) was an important index, presupposing a complete cytogenetic response at 12 months (CCyR12). Patients with IM/BSA >206.7 mg/m(2) showed a higher probability of CCyR12 than others. The IM/BSA (221.7 mg/m(2)) in group ≤300 mg was higher than in group ≥400 mg (207.6 mg/m(2)). The sustained response and survival rate of group ≤300 mg was comparable to that of group ≥400 mg. The plasma trough level of IM was significantly correlated with the IM/BSA. Our study suggests that IM dose adjustments, based on IM/BSA, could improve the clinical outcomes in CML CP patients. © 2015 S. Karger AG, Basel.
    Acta Haematologica 04/2015; 134(1):59-68. DOI:10.1159/000369444 · 1.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical course of generalized pustular psoriasis (GPP) is variable and unpredictable. Sufficient data on the clinical course of the disease has not been reported due to its rarity. To investigate the clinical features and course of GPP according to its subtypes, medical records of patients diagnosed with GPP from 2002 to 2012 at two tertiary hospitals were reviewed. The data included patient demographics, associated symptoms, aggravating factors, patterns of relapse and prognosis. Thirty-three patients with GPP were included in our study, with a mean age of 45.6 years and a male : female ratio of 1:1.2. Patients were categorized based on the following subtypes: acute GPP, 21 (63.6%); GPP of pregnancy, two (6.1%); juvenile GPP, three (9.1%); and annular GPP, seven (21.2%). In the acute GPP population, skin lesions cleared within 2 months in 11 (73.3%) patients, and six (40.0%) of these had no relapse. Severe complications, abortion or death, were observed in two patients (100.0%) with GPP of pregnancy. Nineteen (76.0%) of the GPP patients experienced persistence or relapse of skin lesions. The patterns of skin lesions upon relapse included plaques in six patients (31.6%), pustules in eight patients (42.1%), and plaques and pustules in five patients (26.3%). Among acute GPP patients, 16.7% of patients with no relapse had a history of plaque psoriasis. However, 77.8% of patients with persistence and relapse in their clinical course had a history of plaque psoriasis. In conclusion, our study presents the detailed clinical course of GPP by subtype in Korean patients. © 2015 Japanese Dermatological Association.
    The Journal of Dermatology 03/2015; 42(7). DOI:10.1111/1346-8138.12863 · 2.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The first edition of the Korean treatment guidelines for chronic myelogenous leukemia (CML) was published in 2006. We intend to update those guidelines to include the use of next-generation tyrosine kinase inhibitors (TKIs).
    01/2015; 88(4):406. DOI:10.3904/kjm.2015.88.4.406
  • Source
    Cheol Min Joo · Byung Soo Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we consider a single machine scheduling problems integrating with deterioration effect and rate-modifying activities (RMAs). The scheduling problem assumes that the machine may have multiple RMAs and each job has the processing time with deterioration effect increased depending upon the gap between recent RMA and starting time of the job. In practical industrial applications, the determination of the number and position of RMAs is a critical issue, because the RMAs recover deteriorated processing time of jobs bringing back to normal processing time. In this paper, we simultaneously determine the schedule of time-dependent deteriorating jobs and the number and positions of RMAs to minimize the makespan. To solve the problem, a mathematical model is derived to obtain the optimal solution and hybrid meta-heuristic algorithms are proposed for the problem. The performance of the algorithms is compared using randomly generated examples.
    Journal of Advanced Mechanical Design Systems and Manufacturing 01/2015; 9(1):JAMDSM0007-JAMDSM0007. DOI:10.1299/jamdsm.2015jamdsm0007 · 0.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Despite the advances in acute myeloid leukemia (AML) treatment, the prognosis of elderly patients remains poor and no definitive treatment guideline has been established. In the present study, we aimed to evaluate the effectiveness of intensive chemotherapy in elderly AML patients and to determine which subgroup of patients would be most responsive to the therapy. Methods: We retrospectively analyzed 84 elderly patients: 35, 19, and 30 patients were administered intensive chemotherapy, low-dose chemotherapy, and supportive care, respectively. Results: Among those who received intensive chemotherapy, there were 17 cases of remission after induction chemotherapy; treatment-related mortality was 22.9%. The median overall survival was 7.9 months. Multivariate analysis indicated that the significant prognostic factors for overall survival were performance status, fever before treatment, platelet count, blast count, cytogenetic risk category, and intensive chemotherapy. Subgroup analysis showed that intensive chemotherapy was markedly effective in the relatively younger patients (65-70 years) and those with de novo AML, better-to-intermediate cytogenetic risk, no fever before treatment, high albumin levels, and high lactate dehydrogenase levels. Conclusions: Elderly AML patients had better outcomes with intensive chemotherapy than with low-intensity chemotherapy. Thus, appropriate subgroup selection for intensive chemotherapy is likely to improve therapeutic outcome.
    Acta Haematologica 12/2014; 133(3):300-309. DOI:10.1159/000362777 · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we report a new chemical inhibitor against HIV-1 with a novel structure and mode of action. The inhibitor, designated as A1836, inhibited HIV-1 replication and virus production with a 50% inhibitory concentration (IC50) of 2.0 µM in an MT-4 cell-based and cytopathic protection antiviral assay, while its 50% cytotoxic concentration (CC50) was much higher than 50 µM. Examination of the effect of A1836 on in vitro HIV-1 reverse transcriptase (RT) and integrase showed that neither were molecular targets of A1836. The characterization and re-infection assay of the HIV-1 virions generated in the presence of A1836 showed that the synthesis of early RT products in the cells infected with the virions was inhibited dose-dependently, due in part to abnormal protein formation within the virions, thus resulting in an impaired infectivity. These results suggest that A1836 might be a novel candidate for the development of a new type of HIV-1 inhibitor.
    BMB reports 11/2014; 48(2). DOI:10.5483/BMBRep.2015.48.2.239 · 2.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Basic fibroblast growth factor (bFGF) is a crucial factor sustaining human pluripotent stem cells (hPSCs). We designed this study to search the substitutive factors other than bFGF for the maintenance of hPSCs by using human placenta-derived conditioned medium without exogenous bFGF (hPCCM-), containing CXCR2 ligands including IL-8 and GROα, which was developed on the basis of our previous studies. Firstly, we confirmed that IL-8 and/or GROα play independent roles to preserve the phenotype of hPSCs. And, we tried CXCR2 blockage of hPSCs in hPCCM- and verified the significant decrease of pluripotency-associated genes expression and the proliferation of hPSCs. Interestingly, CXCR2 suppression of hPSCs in mTeSR™1 containing exogenous bFGF decreased the proliferation of hPSCs with maintaining pluripotency characteristics. Lastly, we found that hPSCs proliferated robustly for more than 35 passages in hPCCM- on a gelatin substratum. As well, the higher CXCR2 expression of hPSCs cultured in hPCCM- than those in mTeSR™1 was observable. Our findings suggest that, CXCR2 and its related ligands might be novel factors comparable to bFGF supporting the characteristics of hPSCs and hPCCM- might be useful for the maintenance of hPSCs as well as for the accurate evaluation of CXCR2 role on hPSCs without the confounding influence of exogenous bFGF.
    Stem Cells and Development 11/2014; 24(8). DOI:10.1089/scd.2014.0381 · 3.73 Impact Factor
  • Source
    Eun Ju Lee · Ki Hoon Ahn · Soon Cheol Hong · Eun Hee Lee · Yong Park · Byung Soo Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma, especially non-Hodgkin's lymphoma is extremely rare in pregnancy. A 24-year-old pregnant woman was diagnosed with diffuse large B-cell lymphoma (DLBCL), a subgroup of non-Hodgkin's lymphoma, at 24 weeks' gestation, and was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. After 4 cycles of R-CHOP, she delivered a healthy baby via cesarean section at 34 weeks and 5 days' gestation because of preterm contraction-related fetal distress. The patient was administered the remaining 2 cycles of R-CHOP after delivery. Follow-up magnetic resonance imaging and computed tomography showed complete remission. Here, we report a rare case of DLBCL successfully treated with R-CHOP chemotherapy during pregnancy, we also performed a systematic review of literature for similar cases. There were 3 earlier reports of R-CHOP treatment for DLBCL. All cases, including our case, resulted in preterm birth. Together, these findings suggest that R-CHOP chemotherapy for DLBCL in pregnancy may be associated with preterm birth.
    11/2014; 57(6):526-529. DOI:10.5468/ogs.2014.57.6.526

Publication Stats

4k Citations
490.58 Total Impact Points


  • 2011-2015
    • Busan Veterans Hospital
      Busan, Busan, South Korea
    • King Saud University
      Ar Riyāḑ, Ar Riyāḑ, Saudi Arabia
    • Kangbuk Samsung Hospital
      Sŏul, Seoul, South Korea
  • 1997-2015
    • Kyungpook National University
      • School of Ecological Environment & Ecotourism
      Daikyū, Daegu, South Korea
  • 1993-2015
    • Incheon National University
      • • Department of Industrial and Management Engineering
      • • Department of Information and Telecommunication Engineering
      Sŏul, Seoul, South Korea
    • The Seoul Institute
      Sŏul, Seoul, South Korea
  • 1990-2015
    • Pusan National University
      • • Department of Dermatology
      • • School of Dentistry
      • • Department of Mechanical Engineering
      • • College of Medicine
      Busan, Busan, South Korea
  • 2011-2014
    • University of Seoul
      Sŏul, Seoul, South Korea
  • 2008-2014
    • Hanyang University
      • • Department of Molecular and Life Science
      • • Division of Chemical Engineering and Bioengineering
      Sŏul, Seoul, South Korea
    • Korea Advanced Institute of Science and Technology
      • Department of Electrical Engineering
      Sŏul, Seoul, South Korea
  • 2003-2014
    • Pukyong National University
      • • Division of Systems Management and Engineering
      • • Department of Polymer Engineering
      • • Faculty of Food Science and Biotechnology
      Tsau-liang-hai, Busan, South Korea
    • Catholic University of Korea
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
    • CHA University
      Sŏul, Seoul, South Korea
    • Sejong University
      • Department of Electronic Engineering
      Sŏul, Seoul, South Korea
  • 1997-2014
    • Korea University
      • • Department of Internal Medicine
      • • College of Medicine
      Sŏul, Seoul, South Korea
  • 1995-2014
    • Seoul National University
      • • Department of Chemical and Biological Engineering
      • • Institute of Chemical Processes
      Sŏul, Seoul, South Korea
  • 2013
    • Yeungnam University
      • Department of Neurosurgery
      Daikyū, Daegu, South Korea
  • 1992-2013
    • Yonsei University
      • • Department of Applied Statistics
      • • Cancer Metastasis Research Center
      • • College of Medicine
      Sŏul, Seoul, South Korea
  • 2012
    • Samsung Medical Center
      • Department of Hematology and Oncology
      Sŏul, Seoul, South Korea
    • Gwangju OK Hospital
      Gwangju, Gwangju, South Korea
  • 2007-2012
    • Auburn University
      • Department of Industrial & Systems Engineering
      Auburn, Alabama, United States
    • Konkuk University
      Sŏul, Seoul, South Korea
  • 2001-2012
    • Seoul Medical Center
      Sŏul, Seoul, South Korea
  • 2009
    • Seoul Veterans Hospital
      Sŏul, Seoul, South Korea
    • Inha University
      • Department of Information and Communication Engineering
      Chemulpo, Incheon, South Korea
    • Gyeongsang National University
      Shinshū, Gyeongsangnam-do, South Korea
  • 2008-2009
    • Korea Research Institute of Chemical Technology
      Daiden, Daejeon, South Korea
  • 2006
    • CUNY Graduate Center
      New York City, New York, United States
  • 2005-2006
    • Korea Medical Research Institute
      Sŏul, Seoul, South Korea
  • 1989-2005
    • Yonsei University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 2004
    • Korea Automotive Technology Institute
      Sŏul, Seoul, South Korea
  • 1998-1999
    • University of Michigan
      • Department of Chemical Engineering
      Ann Arbor, Michigan, United States
    • Boston Children's Hospital
      Boston, Massachusetts, United States
  • 1992-1997
    • University of North Carolina at Chapel Hill
      • Department of Biostatistics
      North Carolina, United States
  • 1985
    • National Cancer Center Korea
      QYK, Gyeonggi-do, South Korea